Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026280 | 0.95 | ALDH1A1 (0.43) | ALDH1A1RAB9AL3MBTL1NPC1STING1 | |
| SCHEMBL7028412 | 0.91 | STING1 (0.47) | ALDH1A1RAB9AL3MBTL1NPC1STING1 | |
| SCHEMBL7026274 | 0.91 | ALDH1A1 (0.40) | ALDH1A1RAB9AL3MBTL1NPC1STING1 | |
| SCHEMBL7032737 | 0.81 | STING1 (0.47) | STING1ACHE | |
| SCHEMBL7032225 | 0.81 | MAOB (0.44) | ALDH1A1RAB9AL3MBTL1NPC1MEN1 | |
| SCHEMBL7027417 | 0.77 | STING1 (0.50) | STING1ACHE | |
| SCHEMBL7029339 | 0.77 | STING1 (0.51) | STING1ACHE | |
| SCHEMBL7032230 | 0.76 | CXCR6 (0.44) | ALDH1A1RAB9AL3MBTL1NPC1MEN1 | |
| SCHEMBL7032738 | 0.75 | STING1 (0.45) | STING1ACHE | |
| SCHEMBL7023581 | 0.75 | MMP8 (0.47) | ALDH1A1RAB9ANPC1STING1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109570-A1 | Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases | MITSUI CHEMICALS, INC. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1284265-A1 | BENZOTHIOPHENE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109570-A1 | Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases | PPARG, PPARA, PPARD | ALDH1A1 571/4885RAB9A 4353/4885L3MBTL1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.